Perioperative Management for Patients with Hereditary Angioedema
Open Access
- 1 January 2015
- journal article
- research article
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 6 (1) , 50-5
Abstract
Hereditary angioedema (HAE) is a rare autosomal dominant disease that results from mutations in the C1-esterase inhibitor (C1-INH) gene. HAE is characterized by recurrent episodes of angioedema of the skin (face, extremities, genitalia, trunk), the gastrointestinal tract, and respiratory tract. Symptoms experienced can be debilitating, may impact quality of life, and can be life threatening. Preventing attacks particularly for patients undergoing procedures is critical. Patients with HAE may now treat acute attacks or prevent attacks with medications that have recently become available in the United States; however, these same medications can be used for perioperative management for patients undergoing medical, surgical, and dental procedures. Periprocedural planning is important for patients to reduce the incidence of acute attacks. Education is critical and increasing awareness of short-term prophylaxis options will allow providers to develop an appropriate action plan for their patients. The goal of this review is to increase awareness for HAE treating physicians, surgeons, anesthesia, and emergency room physicians by examining the available treatment options, researching the literature, and summarizing available data for periprocedural management. The availability of treatment options has increased over the past few years, expanding options for physicians and patients living with HAE and improve safety during the perioperative period and at the time of other procedures.Keywords
This publication has 43 references indexed in Scilit:
- HAE Update: Determining optimal patient specific therapyAllergy and Asthma Proceedings, 2013
- Management of hereditary angioedema with C1-inhibitor concentrate during two successive pregnanciesInternational Journal of Gynecology & Obstetrics, 2012
- An update on hereditary angioedemaCurrent Opinion in Pediatrics, 2012
- Successful Hereditary Angioedema Prophylaxis With C1 Inhibitor in Orthognathic SurgeryJournal of Oral and Maxillofacial Surgery, 2012
- Long-term efficacy of danazol treatment in hereditary angioedemaEuropean Journal of Clinical Investigation, 2010
- Long‐term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternativesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Diagnosis and treatment of hereditary angioedema with normal C1 inhibitorAllergy, Asthma & Clinical Immunology, 2010
- Treatment of Hereditary Angioedema: items that need to be addressed in practice parameterAllergy, Asthma & Clinical Immunology, 2010
- Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefitsEuropean Journal Of Dermatology, 2009
- Hereditary Angioedema: Uncomplicated Maxillofacial Surgery Using Short-Term C1 Inhibitor Replacement TherapyInternational Archives of Allergy and Immunology, 1993